RecruitingHeart Failure
Mechanisms of Diuretic Resistance in Heart Failure, Aim 1
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will employ a randomized order, double-blind, repeated measures dose ranging design. This design was chosen in order to generate multiple within-subject serial loop diuretic dose response exposures. The overall study schema will include 75 heart failure (HF) patients.
Sponsor: Yale University
You may qualify if…
- ✓ Clinical diagnosis of HF
- ✓ No plan for titration/change of heart failure medical or device therapies during the study period.
- ✓ Absence of non-elective hospitalizations in the previous 3 months.
- ✓ At optimal volume status by symptoms, exam, and dry weight
- ✓ Age \> 18 years
You may not qualify if…
- ✕ GFR \<20 ml/min/1.73m2 using the Chronic Kidney Disease- Epidemiology (CKD-EPI)equation or use of renal replacement therapies
- ✕ Use of any non-loop type diuretic in the last 14 days with the exclusion of low dose aldosterone antagonist (e.g., spironolactone or eplerenone ≤50 mg). Examples of non-loop diuretics include but may not be limited to acetazolamide (oral or IV, not ophthalmic), metolazone, Hydrochlorothiazide (HCTZ), chlorthalidone, chlorothiazide, indapamide, triamterene, amiloride, finerenone, spironolactone dose \> 50mg day, eplerenone \> 50mg/day,
- ✕ History of flash pulmonary edema requiring hospitalization and treatment with biphasic positive airway pressure or mechanical ventilation or a "brittle" volume sensitive HF phenotype such as an infiltrative or restrictive cardiomyopathy (i.e. amyloid cardiomyopathy, etc).
- ✕ Hemoglobin \< 8 g/dL
- ✕ Pregnant or breastfeeding
- ✕ Inability to give written informed consent or comply with study protocol or follow-up visits
- ✕ Chronic Urinary retention limiting ability to perform timed urine collection procedures
Where it's recruiting
Connecticut
New Haven
Source: ClinicalTrials.gov · NCT05323487 · last updated 2026-05-22